A Phase 2 interventional study of Ranolazine 500 MG and Ranolazine 1000 MG in ALS, sponsored by University of Kansas Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-09.
Sponsored by University of Kansas Medical Center · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this research study is to evaluate the safety and effectiveness of Ranolazine, and how well it is tolerated in patients with Amyotrophic Lateral Sclerosis (ALS). Ranolazine is an FDA approved drug that is used for decreasing chest pain.
Amyotrophic Lateral Sclerosis (ALS) is a progressive debilitating and fatal neurodegenerative disease involving the motor neurons in the primary motor cortex, corticospinal tracts, brainstem and spinal cord with 5,000 newly diagnosed patients per year in the USA. There is a pressing need for additional therapies, as the only two FDA-approved drugs for ALS, riluzole and edaravone, showed prolongation of median survival of only two to three months and only a modest benefit in daily functioning, respectively. The ability to identify FDA approved drugs which can be repurposed to ALS, and which may slow disease progression, alleviate symptoms, or prolong survival will have an immediate positive impact of the lives of patients with ALS and their family members. Hypothesis: Ranolazine, an FDA approved drug for angina which inhibits the late Na+ current and intracellular Ca2+ accumulation may be neuroprotective in ALS by reducing neuronal hyperexcitability, may slow disease progression and reduce cramp frequency.
University of Kansas Medical Center is the lead sponsor of 492 studies on the registry; 110 are open to participants now.
Of its 38 completed or terminated interventional studies of FDA-regulated products, 24 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will take Ranolazine 500mg twice daily for up to 4 weeks.
Drug: Ranolazine 500 MG
Participants will take Ranolazine 1000mg twice daily for up to 4 weeks.
Drug: Ranolazine 1000 MG
Ranolazine is an FDA approved drug for angina (ongoing chest pain or pressure that is felt when the heart does not get enough oxygen).
Ranolazine is an FDA approved drug for angina (ongoing chest pain or pressure that is felt when the heart does not get enough oxygen).
Dose Limiting Toxicities (DLT)
Measured as any drug-related serious adverse event, or drug-related adverse event necessitating study withdrawal. If a dose has less than 33% DLTs it will be considered tolerable.
Time frame: Up to Week 12
Percent Change in Cramp Frequency
The percent change in cramp frequency: average daily cramp frequency, comparing week 12-baseline
Time frame: Weekly for 12 weeks
Percentage Change in Average Weekly Cramp Severity
Percent change in average weekly cramp severity (1 being a very mild muscle cramp and 10 being the most severe cramp you ever experienced)
Time frame: Weekly for 12 weeks
Change in Nocturnal Awakenings Per Week, Comparing Week 12 to Baseline
Time frame: Weekly for 12 weeks
Muscle Fasciculations Count
Time frame: Up to week 12
| Milestone | Ranolazine 500mg | Ranolazine 1000mg |
|---|---|---|
| Started | 6 | 8 |
| Completed | 6 | 4 |
| Not completed | 0 | 4 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Adverse event | 0 | 3 |
Measured as any drug-related serious adverse event, or drug-related adverse event necessitating study withdrawal. If a dose has less than 33% DLTs it will be considered tolerable.
| Participants | Ranolazine 500mg | Ranolazine 1000mg |
|---|---|---|
| Dose Limiting Toxicities (DLT) | 1 | 2 |
The percent change in cramp frequency: average daily cramp frequency, comparing week 12-baseline
| Percent Change in Cramp Frequency | Ranolazine 500mg | Ranolazine 1000mg |
|---|---|---|
| Percent Change in Cramp Frequency | -39.98 ± 23.94 | -68.38 ± 27.74 |
Percent change in average weekly cramp severity (1 being a very mild muscle cramp and 10 being the most severe cramp you ever experienced)
| Percentage change in average weekly cram | Ranolazine 500mg | Ranolazine 1000mg |
|---|---|---|
| Percentage Change in Average Weekly Cramp Severity | -38.68 ± 19.46 | -54.05 ± 39.94 |
| Number of nights awakened | Ranolazine 500mg | Ranolazine 1000mg |
|---|---|---|
| Change in Nocturnal Awakenings Per Week, Comparing Week 12 to Baseline | -1.67 ± 2.09 | -4.57 ± 6.80 |
| Muscle fasciculations count | Ranolazine 500mg | Ranolazine 1000mg |
|---|---|---|
| Muscle Fasciculations Count | 33 ± 25 | 58 ± 25 |
Collected over Adverse event data was collected for 12 weeks. This began at baseline visit through the week 12 visit.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranolazine 500mg | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Ranolazine 1000mg | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| Event | Ranolazine 500mg | Ranolazine 1000mg |
|---|---|---|
| ConstipationGastrointestinal disorders | 1/6 | 4/8 |
| Upper respiratory infectionInfections and infestations | 3/6 | 1/8 |
| Gastroesophageal refluxGastrointestinal disorders | 1/6 | 2/8 |
| InfluenzaInfections and infestations | 0/6 | 2/8 |
| DrowsinessGeneral disorders | 0/6 | 2/8 |
| SinusitisInfections and infestations | 1/6 | 0/8 |
| DizzinessEar and labyrinth disorders | 0/6 | 1/8 |
| IndigestionGastrointestinal disorders | 0/6 | 1/8 |
| Dental AbscessInfections and infestations | 0/6 | 1/8 |
| DepressionPsychiatric disorders | 0/6 | 1/8 |
| Age, Categorical(Participants) | Ranolazine 500mg | Ranolazine 1000mg | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 5 | 6 | 11 |
| >=65 years | 1 | 2 | 3 |
| Age, Continuous(years) | Ranolazine 500mg | Ranolazine 1000mg | Total |
|---|---|---|---|
| Median | 53 (42 to 67) | 55 (39 to 71) | 54 (39 to 71) |
| Sex: Female, Male(Participants) | Ranolazine 500mg | Ranolazine 1000mg | Total |
|---|---|---|---|
| Female | 1 | 2 | 3 |
| Male | 5 | 6 | 11 |
| Race/Ethnicity, Customized(Participants) | Ranolazine 500mg | Ranolazine 1000mg | Total |
|---|---|---|---|
| Caucasian | 6 | 8 | 14 |
| Non Hispanic | 6 | 8 | 14 |
| Region of Enrollment(participants) | Ranolazine 500mg | Ranolazine 1000mg | Total |
|---|---|---|---|
| United States | 6 | 8 | 14 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2018 to primary completion in Dec 2020, 30 months.
Results were first posted in Dec 2024, 3 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranolazine
University of Kansas Medical Center →